Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
cytochrome c CRISPR/Cas9 KO Plasmid (h): sc-417607
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- cytochrome c CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the cytochrome c genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: cytochrome c Antibody (A-8): sc-13156
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
cytochrome c CRISPR/Cas9 KO Plasmid (h) | sc-417607 | 20 µg | $397.00 |
Overview
CYCS encodes human cytochrome c, a heme-containing electron carrier in the mitochondrial intermembrane space that transfers electrons between complex III (cytochrome bc1) and complex IV (cytochrome c oxidase) to support oxidative phosphorylation and cellular ATP production. Beyond bioenergetics, cytochrome c is a central mediator of intrinsic apoptosis, where mitochondrial outer membrane permeabilization enables its cytosolic release and subsequent apoptosome assembly with APAF1 and caspase-9. CYCS function intersects with redox homeostasis, mitochondrial dynamics, and stress-response signaling, making it broadly relevant to studies of mitochondrial dysfunction. Altered cytochrome c–dependent respiration and apoptotic competence are frequently examined in contexts such as neurodegeneration, cardiometabolic injury, and cancer cell survival phenotypes.
cytochrome c CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CYCS gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CYCS together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CYCS open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish cytochrome c protein expression.
This CRISPR knockout system enables efficient generation of CYCS-deficient cell models for investigation of cytochrome c signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CYCS exon(s) critical for cytochrome c function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CYCS genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by cytochrome c CRISPR/Cas9 KO Plasmid (h) and cytochrome c CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CYCS locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by cytochrome c HDR Plasmid (h) and cytochrome c HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CYCS homology arms to support homology-directed repair at defined CYCS target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.